Online inquiry

IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9638MR)

This product GTTS-WQ9638MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 608
UniProt ID P07766; Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9638MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1644MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ14514MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ1765MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ3349MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ6370MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ3723MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ12523MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ15688MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VEGF Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW